SCHEDULE: Gilead Boosts Xilio Stake to 19.9%

Gilead Sciences, Inc. has increased its beneficial ownership in Xilio Therapeutics, Inc. to 19.9% of common stock, holding over 10.6 million shares.

Summary

• Gilead Sciences, Inc. reported beneficial ownership of 10,613,944 shares of Xilio Therapeutics, Inc. common stock.
• This represents 19.9% of Xilio's outstanding common stock.
• The ownership includes shares issued on March 28, 2024 (6,860,223 shares), April 3, 2024 (485,250 shares), December 18, 2024 (1,759,978 shares), and 1,508,493 shares from pre-funded warrants.
• The percentage is based on 51,827,910 shares of common stock outstanding as of August 8, 2025, as disclosed in Xilio's Form 10-Q.
• Gilead holds sole voting and dispositive power over all 10,613,944 shares.

Sentiment

Score: 7

Explanation: The filing indicates a significant and growing strategic investment by a major pharmaceutical company (Gilead) in a smaller biotech firm (Xilio), suggesting confidence and potential future collaboration or acquisition. While a 13G is purely factual, the nature of the investment is generally positive for Xilio.

Positives

• Gilead Sciences, a major biopharmaceutical company, increasing its stake suggests confidence in Xilio Therapeutics' long-term potential or strategic value.
• A significant institutional investor holding nearly 20% can provide stability and potentially open doors for future collaborations or partnerships.
• The accumulation of shares over time (March 2024, April 2024, December 2024) indicates a sustained investment strategy.

Negatives

• The filing itself does not contain negative financial or operational information about Xilio Therapeutics.
• A large stake by one entity, even if passive, could limit the float and liquidity of the stock.

Risks

• The filing states the shares were not acquired for the purpose of changing or influencing control, but a large stake always carries the potential for future influence, which could be a risk for other shareholders if interests diverge.
• The value of Gilead's investment is subject to the performance and market fluctuations of Xilio Therapeutics' common stock.

Future Outlook

The Schedule 13G filing is a disclosure of current ownership and does not contain forward-looking statements or guidance regarding Xilio Therapeutics' future operations or financial performance.

Management Comments

• The filing includes a certification by Andrew D. Dickinson, Executive Vice President and Chief Financial Officer of Gilead Sciences, Inc., stating that the securities were not acquired or held for the purpose of changing or influencing control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.

Industry Context

Gilead Sciences, a global biopharmaceutical company, increasing its stake in Xilio Therapeutics, a clinical-stage biotechnology company, highlights continued strategic interest from larger pharmaceutical firms in innovative biotech assets. This type of significant investment can signal potential future collaborations, partnerships, or even acquisition interest in the highly competitive and capital-intensive biotechnology sector, where larger players often seek to expand their pipelines through strategic investments.

Comparison to Industry Standards

• While a Schedule 13G does not provide performance metrics for direct comparison, Gilead's 19.9% stake in Xilio Therapeutics is a substantial minority interest.
• Such a significant stake by a major pharmaceutical company like Gilead (a leader in antiviral drugs, HIV, and liver diseases) in a smaller biotech firm (Xilio focuses on tumor-selective immuno-oncology therapies) is common in the industry.
• Similar strategic investments or partnerships have been seen with companies like Bristol Myers Squibb investing in smaller oncology biotechs or Pfizer acquiring stakes in companies with promising early-stage assets.
• This level of ownership often precedes deeper collaborations or potential M&A activities, aligning with industry trends where large pharma companies leverage their capital and expertise to support and potentially integrate innovative smaller biotechs.

Related Party Transactions

• Gilead Sciences, Inc. holds a 19.9% beneficial ownership stake in Xilio Therapeutics, Inc., making it a significant related party due to its substantial influence potential, even if passive according to the filing's certification.

Stakeholder Impact

• Shareholders: Increased confidence due to a major institutional investor's significant stake, potentially leading to increased stock stability and future strategic opportunities.
• Employees: Potential for increased stability and resources if the investment leads to deeper collaboration or partnership.
• Customers/Patients: No direct immediate impact, but long-term potential for accelerated drug development if the investment facilitates Xilio's programs.

Next Steps

• The filing does not explicitly state future actions or milestones for Xilio Therapeutics or Gilead Sciences beyond the disclosure of ownership.

Key Dates

Recommendation

While Gilead's significant and growing stake in Xilio Therapeutics is a positive signal, indicating potential strategic value and future collaboration, this Schedule 13G filing is purely an ownership disclosure and does not provide new operational or financial performance data for Xilio. The investment suggests a long-term strategic alignment, but without further details on Xilio's clinical progress, financial health, or specific partnership terms, a 'hold' recommendation is prudent for existing investors. New investors might consider initiating a position based on the implied strategic validation, but should await more comprehensive operational updates from Xilio.

Keywords

Xilio Therapeutics, Gilead Sciences, Common Stock, Schedule 13G, Beneficial Ownership, Biotechnology, Pharmaceuticals, Investment, Equity Stake, SEC Filing